ReviewCurrent allergy and asthma reports2026
Targeting Mast Cells in Chronic Spontaneous Urticaria.
Review in Current allergy and asthma reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Histamine-Mediated Syndrome (HMS): Beyond Allergy and Therapeutic Potential of Immunoglobulin/Histamine Complex (IHC).International journal of molecular sciences · 2026Review
- Novel Benzothiadiazine Derivatives as MRGX2 Antagonists for Treating Chronic Spontaneous Urticaria.ACS medicinal chemistry letters · 2026Article
- Type 2 Inflammatory Diseases: The Crossroads of Immunity and Metabolism.Research (Washington, D.C.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review focuses on the pathophysiology, diagnostic approach, and current and emerging treatments of chronic spontaneous urticaria (CSU), with an emphasis on mast-cell mediated mechanisms and therapeutic targets. RECENT
findingsCSU is a mast-cell mediated disease involving both immunoglobulin E (IgE) and non-IgE mediated pathways, thus targeting mast cells and their downstream mediators can provide therapeutic benefit. Emerging therapies such as dupilumab, Bruton's tyrosine kinase (BTK) inhibitors, anti-KIT antibodies, Janus kinase (JAK) inhibitors, Mas-related G protein-coupled receptor X2 (MRGPRX2) inhibitors, interleukin (IL)-17 and IL-5 inhibitors, anti-thymic stromal lymphopoietin (TSLP) monoclonal antibodies, and mast cell silencers, as well as lifestyle changes such as low-histamine diets, are under investigation for antihistamine- refractory disease. While current international guidelines recommend second-generation H1-antihistamines as first-line treatments of CSU, novel treatments targeting mast-cell mediated pathways show promise for refractory disease. Recent advancements in targeted therapies and biomarkers may improve treatment personalization and response.
Indexed as
Identifiers
41697480What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.